Everfront Biotech Inc

Taipei, Taiwan

Everfront Biotech Inc

Taipei, Taiwan
SEARCH FILTERS
Time filter
Source Type

Patent
Everfront Biotech Inc. | Date: 2017-03-01

A stable pharmaceutical composition, containing: (a) a medium system, containing a first component, a second component, and a third component, wherein the first component is a phosphate buffer solution; the second component is selected from the group consisting of: vegetable oils, animal oils, fatty acids and a combination thereof; and the third component is selected from the group consisting of: polyethylene glycol, dimethyl sulfoxide, ethanol, polypropylene glycol, polysorbate, polyoxyethylated vegetable oil, ethyl acetate, hydroxyethyl 12-hydroxy stearate, vitamin E, polyethylene glycol succinate, and a combination thereof, and (b) n-butylidenephthalide (BP).


Patent
Everfront Biotech Inc. | Date: 2017-08-23

A method for preparing an isobenzofuran-1(3H)-one compound having the following formula I, wherein R1, R2 and p are as defined in the description.


Patent
Everfront Biotech Inc. | Date: 2017-05-10

Disclosed is a use of phthalide compound for the preparation of a medicament. The medicament is especially used for treating and/or delaying the degeneration of Purkinje cells, and the phthalide compound is selected from the following group: butylidene phthalide, a metabolic precursor of butylidene phthalide, a pharmaceutically acceptable salt of the metabolic precursor of butylidene phthalide, a pharmaceutically acceptable ester of the metabolic precursor of butylidene phthalide, and any combination of the foregoing.


Rajamani K.,National Dong Hwa University | Liu J.-W.,National Dong Hwa University | Liu J.-W.,Everfront Biotech Inc. | Wu C.-H.,National Dong Hwa University | And 7 more authors.
Neuropharmacology | Year: 2017

Spinocerebellar ataxia type 3 or Machado-Joseph disease (SCA3/MJD) is characterized by the repetition of a CAG codon in the ataxin-3 gene (ATXN3), which leads to the formation of an elongated mutant ATXN3 protein that can neither be denatured nor undergo proteolysis in the normal manner. This abnormal proteolysis leads to the accumulation of cleaved fragments, which have been identified as toxic and further they act as a seed for more aggregate formation, thereby increasing toxicity in neuronal cells. To date, there have been few studies or treatment strategies that have focused on controlling toxic fragment formation. The aim of this study is to develop a potential treatment strategy for addressing the complications of toxic fragment formation and to provide an alternative treatment strategy for SCA3. Our preliminary data on anti-aggregation and toxic fragment formation using an HEK (human embryonic kidney cells) 293T-84Q-eGFP (green fluorescent protein) cell model identified n-butilydenephthalide (n-BP) as a potential drug treatment for SCA3. n-BP decreased toxic fragment formation in both SCA3 cell and animal models. Moreover, results showed that n-BP can improve gait, motor coordination, and activity in SCA3 mice. To comprehend the molecular basis behind the control of toxic fragment formation, we used microarray analysis to identify tryptophan metabolism as a major player in controlling the fate of mutant ATXN3 aggregates. We also demonstrated that n-BP functions by regulating the early part of the kynurenine pathway through the downregulation of tryptophan 2, 3-dioxygenase (TDO2), which decreases the downstream neurotoxic product, quinolinic acid (QA). In addition, through the control of TDO2, n-BP also decreases active calpain levels, an important enzyme involved in the proteolysis of mutant ATXN3, thereby decreasing toxic fragment formation and associated neurotoxicity. Collectively, these findings indicate a correlation between n-BP, TDO2, QA, calpain, and toxic fragment formation. Thus, this study contributes to a better understanding of the molecular interactions involved in SCA3, and provides a novel potential treatment strategy for this neurodegenerative disease. © 2017 Elsevier Ltd


Ho T.-J.,China Medical University at Taichung | Ho T.-J.,China Medical University Beigang Hospital | Chan T.-M.,China Medical University at Taichung | Chan T.-M.,Everfront Biotech Inc | And 10 more authors.
Cell Transplantation | Year: 2014

This review reports on recent findings concerning the effects of acupuncture and electroacupuncture (EA) on stem cell mobilization and differentiation, in particular with regard to neurogenesis. Traditional Chinese acupuncture has a history of over 2,500 years and is becoming more popular worldwide. Evidence has demonstrated that acupuncture may be of benefit in stroke rehabilitation, parkinsonism, dementia, and depression. This article reviews recent studies concerning the effects of acupuncture/EA on stem cell mobilization and on progenitor cell proliferation in the CNS. The reviewed evidence indicates that acupuncture/EA has beneficial effects in several neurodegenerative diseases, and it may prove to be a nondrug method for mobilizing stem cells in the CNS. © 2014 Cognizant Comm. Corp.


Chan T.-M.,China Medical University at Taichung | Chan T.-M.,Everfront Biotech Inc | Harn H.-J.,China Medical University at Taichung | Lin H.-P.,National Health Research Institute | And 11 more authors.
Cell Transplantation | Year: 2014

Stroke is one of the disorders for which clinically effective therapeutic modalities are most needed, and numerous ways have been explored to attempt to investigate their feasibilities. However, ischemic- or hemorrhagicinduced inflammatory neuron death causes irreversible injuries and infarction regions, and there are currently no truly effective drugs available as therapy. It is therefore urgent to be able to provide a fundamental treatment method to regenerate neuronal brain cells, and therefore, the use of stem cells for curing chronic stroke could be a major breakthrough development. In this review, we describe the features and classification of stroke and focus on the benefits of adipose tissue-derived stem cells and their applications in stroke animal models. The results show that cell-based therapies have resulted in significant improvements in neuronal behaviors and functions through different molecular mechanisms, and no safety problems have so far arisen after transplantation. Further, we propose a clinical possibility to create a homing niche by reducing the degree of invasive intracerebroventricular transplantation and combining it with continuous intravenous administration to achieve a complete cure. © 2014 Cognizant Comm. Corp.


Huang M.-H.,National Chung Hsing University | Lin S.-Z.,China Medical University at Taichung | Lin S.-Z.,China Medical University Beigan Hospital | Lin P.-C.,Applied Cell Technology | And 10 more authors.
Tumor Biology | Year: 2014

Developing an effective drug for treating human glioblastoma multiform (GBM) has been investigated persistently. A pure compound butylidenephthalide (BP), isolated from Angelica sinensis, has been shown the activities to arrest the growth and initiate apoptosis of GBM in our previous reports. In this study, we further demonstrated that BP treatment accelerates the cell senescence in a dose-dependent manner in vitro and in vivo. S-phase kinase-associated protein 2 (Skp2), a proto-oncogene, is generally upregulated in cancer. We found that it was downregulated in BP-treated GBM cells. The downregulation of Skp2 is parallel with increasing p16 and p21 expression which causes G0/G1 arrest and tumor cell senescence. We also found that restoring the Skp2 protein level by exogenous overexpression prevents the BP-induced cell senescence. Therefore, the linkage between cell senescence and Skp2 expression is strengthened. Promoter binding analysis further detailed that the BP-mediated SP1 reduction might involve in the Skp2 downregulation. In summary, these results emphasize that BP-triggered senescence in GBMcells is highly associated with its control on Skp2 regulation. © International Society of Oncology and BioMarkers (ISOBM) 2014.


Chiu S.-C.,China Medical University at Taichung | Chung H.-Y.,China Medical University at Taichung | Chung H.-Y.,China Medical University Beigan Hospital | Cho D.-Y.,China Medical University at Taichung | And 12 more authors.
Cell Transplantation | Year: 2014

The first microRNA, let-7, and its family were discovered in Caenorhabditis elegans and are functionally conserved from worms to humans in the regulation of embryonic development and stemness. The let-7 family has been shown to have an essential role in stem cell differentiation and tumor-suppressive activity. Deregulating expression of let-7 is commonly reported in many human cancers. Emerging evidence has accumulated and suggests that reestablishment of let-7 in tumor cells is a valuable therapeutic strategy. However, findings reach beyond tumor therapeutics and may impinge on stemness and differentiation of stem cells. In this review, we discuss the role of let-7 in development and differentiation of normal adult stem/progenitor cells and offer a viewpoint of the association between deregulated let-7 expression and tumorigenesis. The regulation of let-7 expression, cancer-relevant let-7 targets, and the application of let-7 are highlighted. © 2014 Cognizant Comm. Corp.


Patent
Everfront Biotech Inc. | Date: 2015-04-24

A pharmaceutical composition comprising:


Patent
Everfront Biotech Inc. | Date: 2014-10-01

A method for treating and/or delaying the degeneration of Purkinje cells in a subject is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a medicament, wherein the medicament comprises a phthalide selected from the group consisting of n-butylidenephthalide (BP), a metabolic precursor of BP, a pharmaceutically acceptable salt of a metabolic precursor of BP, a pharmaceutically acceptable ester of a metabolic precursor of BP, and combinations thereof.

Loading Everfront Biotech Inc collaborators
Loading Everfront Biotech Inc collaborators